A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
Brief description of study
If you have been diagnosed with either prostate, lung cancer, breast cancer, ovarian cancer, or urothelial cancer you may qualify to participate in a study to learn about the effects of the study drugs, avelumab (anti-PD-L1 immunotherapy and talazoparib (PARP inhibitor), when given as an investigational combination treatment for your cancer. The goal of this phase 1/2 study is to assess the safety and early signs of efficacy of the avelumab and talazoparib combination in patients with locally advanced (primary or recurrent) or metastatic solid tumors.
Clinical Study Identifier: s17-01353
ClinicalTrials.gov Identifier: NCTs17-01353
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.